Medtronic plc (MDT.VI)

74.41 0.00 (0.00%) At close: 05:32PM CEST

Medtronic plc

20 On Hatch
Lower Hatch Street
Dublin 2
Ireland
353 1 438 1700
https://www.medtronic.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 95,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Geoffrey Straub Martha	Chairman of the Board & CEO	1.67M	N/A	1970
Ms. Karen L. Parkhill	Executive VP & CFO	926.55k	N/A	1965
Mr. Sean M. Salmon	Executive VP & President of Cardiovascular Portfolio	841.32k	390.99k	1965
Mr. Robert J. W. ten Hoedt	Executive VP & President of Global Regions	1.16M	89.65k	1960
Mr. Mark Ploof	Senior Vice President of Global Operations and Business Services	N/A	N/A	N/A
Ms. Jennifer M. Kirk	Senior VP, Global Controller & Chief Accounting Officer	N/A	N/A	1975
Dr. Kenneth E. Washington Ph.D.	Senior VP and Chief Technology & Innovation Officer	N/A	N/A	1960
Dr. Laura Mauri M.D., M.Sc.	Senior VP and Chief Scientific & Medical Officer	N/A	N/A	N/A
Mr. Ryan Weispfenning	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Ivan K. Fong	Executive VP, General Counsel & Secretary	920.32k	N/A	1961

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Corporate governance

Medtronic plc’s ISS governance QualityScore as of 1 June 2024 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.